Patents by Inventor Sally J. DeNardo
Sally J. DeNardo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11285165Abstract: This invention provides novel polydentate selective high affinity ligands (SHALs) that can be used in a variety of applications in a manner analogous to the use of antibodies. SHALs typically comprise a multiplicity of ligands that each bind different region son the target molecule. The ligands are joined directly or through a linker thereby forming a polydentate moiety that typically binds the target molecule with high selectivity and avidity.Type: GrantFiled: April 8, 2020Date of Patent: March 29, 2022Assignees: Lawrence Livermore National Security, LLC, The Regents of the University of CaliforniaInventors: Sally J. DeNardo, Gerald L. DeNardo, Rodney L. Balhorn
-
Publication number: 20210000843Abstract: This invention provides novel polydentate selective high affinity ligands (SHALs) that can be used in a variety of applications in a manner analogous to the use of antibodies. SHALs typically comprise a multiplicity of ligands that each bind different region son the target molecule. The ligands are joined directly or through a linker thereby forming a polydentate moiety that typically binds the target molecule with high selectivity and avidity.Type: ApplicationFiled: April 8, 2020Publication date: January 7, 2021Applicants: LAWRENCE LIVERMORE NATIONAL SECURITY, LLC, THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Sally J. DeNardo, Gerald L. DeNardo, Rodney L. Balhorn
-
Patent number: 10874678Abstract: This invention provides novel polydentate selective high affinity ligands (SHALs) that can be used in a variety of applications in a manner analogous to the use of antibodies. SHALs typically comprise a multiplicity of ligands that each bind different region son the target molecule. The ligands are joined directly or through a linker thereby forming a polydentate moiety that typically binds the target molecule with high selectivity and avidity.Type: GrantFiled: February 28, 2019Date of Patent: December 29, 2020Assignees: LAWRENCE LIVERMORE NATIONAL SECURITY, LLC, THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Sally J. DeNardo, Gerald L. DeNardo, Rodney L. Balhorn
-
Patent number: 10646502Abstract: This invention provides novel polydentate selective high affinity ligands (SHALs) that can be used in a variety of applications in a manner analogous to the use of antibodies. SHALs typically comprise a multiplicity of ligands that each bind different region son the target molecule. The ligands are joined directly or through a linker thereby forming a polydentate moiety that typically binds the target molecule with high selectivity and avidity.Type: GrantFiled: September 13, 2017Date of Patent: May 12, 2020Assignee: Lawrence Livermore National SecurityInventors: Sally J. DeNardo, Gerald L. DeNardo, Rodney L. Balhorn
-
Publication number: 20190262364Abstract: This invention provides novel polydentate selective high affinity ligands (SHALs) that can be used in a variety of applications in a manner analogous to the use of antibodies. SHALs typically comprise a multiplicity of ligands that each bind different region son the target molecule. The ligands are joined directly or through a linker thereby forming a polydentate moiety that typically binds the target molecule with high selectivity and avidity.Type: ApplicationFiled: February 28, 2019Publication date: August 29, 2019Applicants: LAWRENCE LIVERMORE NATIONAL SECURITY, LLC, THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Sally J. DeNardo, Gerald L. DeNardo, Rodney L. Balhorn
-
Patent number: 10292992Abstract: This invention provides novel polydentate selective high affinity ligands (SHALs) that can be used in a variety of applications in a manner analogous to the use of antibodies. SHALs typically comprise a multiplicity of ligands that each bind different region son the target molecule. The ligands are joined directly or through a linker thereby forming a polydentate moiety that typically binds the target molecule with high selectivity and avidity.Type: GrantFiled: September 13, 2017Date of Patent: May 21, 2019Assignees: Lawrence Livermore National Security, LLC, The Regents of the University of CaliforniaInventors: Sally J. DeNardo, Gerald L. DeNardo, Rodney L. Balhorn
-
Patent number: 9884070Abstract: This invention provides novel polydentate selective high affinity ligands (SHALs) that can be used in a variety of applications in a manner analogous to the use of antibodies. SHALs typically comprise a multiplicity of ligands that each bind different region son the target molecule. The ligands are joined directly or through a linker thereby forming a polydentate moiety that typically binds the target molecule with high selectivity and avidity.Type: GrantFiled: April 21, 2009Date of Patent: February 6, 2018Assignees: Lawrence Livermore National Security, LLC, The Regents of the University of CaliforniaInventors: Sally J. Denardo, Gerald L. Denardo, Rodney L. Balhorn
-
Publication number: 20180008622Abstract: This invention provides novel polydentate selective high affinity ligands (SHALs) that can be used in a variety of applications in a manner analogous to the use of antibodies. SHALs typically comprise a multiplicity of ligands that each bind different region son the target molecule. The ligands are joined directly or through a linker thereby forming a polydentate moiety that typically binds the target molecule with high selectivity and avidity.Type: ApplicationFiled: September 13, 2017Publication date: January 11, 2018Applicants: LAWRENCE LIVERMORE NATIONAL SECURITY, LLC, THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Sally J. DeNardo, Gerald L. DeNardo, Rodney L. Balhorn
-
Publication number: 20180008621Abstract: This invention provides novel polydentate selective high affinity ligands (SHALs) that can be used in a variety of applications in a manner analogous to the use of antibodies. SHALs typically comprise a multiplicity of ligands that each bind different region son the target molecule. The ligands are joined directly or through a linker thereby forming a polydentate moiety that typically binds the target molecule with high selectivity and avidity.Type: ApplicationFiled: September 13, 2017Publication date: January 11, 2018Applicants: LAWRENCE LIVERMORE NATIONAL SECURITY, LLC, THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Sally J. DeNardo, Gerald L. DeNardo, Rodney L. Balhorn
-
Publication number: 20110144065Abstract: This invention provides novel polydentate selective high affinity ligands (SHALs) that can be used in a variety of applications in a manner analogous to the use of antibodies. SHALs typically comprise a multiplicity of ligands that each bind different region son the target molecule. The ligands are joined directly or through a linker thereby forming a polydentate moiety that typically binds the target molecule with high selectivity and avidity.Type: ApplicationFiled: April 21, 2009Publication date: June 16, 2011Inventors: Sally J. Denardo, Gerald L. Denardo, Rodney L. Balhorn
-
Publication number: 20100179303Abstract: A new radioconjugate NP has been developed using recombinant antibody fragments, di-scFv-c (111 In-DOTA-di-scFv-NP) for imaging and therapy of anti MUC-1 10 expressing cancers since aberrant MUC-1 Is abundantly expressed on the majority of human epithelial cancers. Selection and engineering of anti-MUC-1 di-scFv-c (50 kDa) was generated to link NP-M (maleimide). DOTA chelate was conjugated with di-scFv-c for the radiometal chelation to trace the RINP at in vivo. This RINP preparation can provide uniquely high tumor cell binding NP for AMF driven tumor hyperthermia.Type: ApplicationFiled: April 25, 2008Publication date: July 15, 2010Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Arutselvan Natarajan, Sally J. Denardo, Gerald L. Denardo, Cordula Gruettner
-
Patent number: 7029652Abstract: A method of treating tumors, such as prostate tumors, breast tumors, non-Hodgkin's lymphoma, and the like, includes the sequential steps of administering to the patient at least one dose of an antiangiogenic cyclo-arginine-glycine-aspartic acid-containing pentapeptide (cRGD pentapeptide); administering to the patient an anti-tumor effective amount of a radioimmunotherapeutic agent (RIT); and then administering to the patient at least one additional dose of cRGD pentapeptide. The cRGD pentapeptide is preferably cyclo-(Arg-Gly-Asp-D-Phe-[N-Me]-Val), and the RIT is preferably a radionuclide-labeled chelating agent-ligand complex in which chelating agent is chemically bonded to a tumor-targeting molecule, such as a monoclonal antibody.Type: GrantFiled: July 31, 2002Date of Patent: April 18, 2006Assignees: The Regents of the University of California, Merck Patent GmbHInventors: Sally J. DeNardo, Patricia A. Burke, Gerald L. DeNardo, Simon Goodman, Kerstin Matzku, legal representative, Siegfried Matzku, deceased
-
Publication number: 20030143157Abstract: A method of treating tumors, such as prostate tumors, breast tumors, non-Hodgkin's lymphoma, and the like, includes the sequential steps of administering to the patient at least one dose of an antiangiogenic cyclo-arginine-glycine-aspartic acid-containing pentapeptide (cRGD pentapeptide); administering to the patient an anti-tumor effective amount of a radioimmunotherapeutic agent (RIT); and then administering to the patient at least one additional dose of cRGD pentapeptide. The cRGD pentapeptide is preferably cyclo-(Arg-Gly-Asp-D-Phe-[N-Me]-Val), and the RIT is preferably a radionuclide-labeled chelating agent-ligand complex in which chelating agent is chemically bonded to a tumor-targeting molecule, such as a monoclonal antibody.Type: ApplicationFiled: July 31, 2002Publication date: July 31, 2003Inventors: Sally J. DeNardo, Patricia A. Burke, Gerald L. DeNardo, Simon Goodman, Siegfried Matzku
-
Patent number: 5958374Abstract: Radionuclide-labeled chelating agent-ligand complexes that are useful in medical diagnosis or therapy are prepared by reacting a radionuclide, such as .sup.90 Y or .sup.111 In, with a polyfunctional chelating agent to form a radionuclide chelate that is electrically neutral; purifying the chelate by anion exchange chromatography; and reacting the purified chelate with a targeting molecule, such as a monoclonal antibody, to form the complex.Type: GrantFiled: December 17, 1996Date of Patent: September 28, 1999Assignee: The Regents of the University of CaliforniaInventors: Claude F. Meares, Min Li, Sally J. DeNardo
-
Patent number: 4678667Abstract: A copper chelate conjugate which is stable in human serum. The conjugate includes the copper chelate of a cyclic tetraaza di-, tri-, or tetra-acetic acid, a linker attached at one linker end to a ring carbon of the chelate, and a biomolecule joined at the other end of the linker. The conjugate, or the linker-copper chelate compound used in forming the conjugate, are designed for use in diagnostic and therapeutic applications which involve Cu(II) localization via the systemic route.Type: GrantFiled: July 2, 1985Date of Patent: July 7, 1987Assignee: 501 Regents of the University of CaliforniaInventors: Claude F. Meares, Sally J. DeNardo, William C. Cole, Min K. Mol